In a filing, Krystal Biotech Inc revealed its President, R&D Krishnan Suma unloaded Company’s shares for reported $4.12 million on Dec 13 ’24. In the deal valued at $164.82 per share,25,000 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,537,262 shares worth roughly $228.11 million.
Then, Krishnan Suma sold 25,000 shares, generating $4,119,524 in total proceeds. Upon selling the shares at $164.78, the President, R&D now owns 1,475,882 shares.
Before that, Krishnan Krish S sold 25,000 shares. Krystal Biotech Inc shares valued at $4,120,499 were divested by the President and CEO at a price of $164.82 per share. As a result of the transaction, Krishnan Krish S now holds 1,537,262 shares, worth roughly $228.11 million.
Citigroup downgraded its Krystal Biotech Inc [KRYS] rating to a Neutral from a a Buy in a research note published on August 06, 2024; the price target was increased to $204 from $195. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid November with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering KRYS with “an Overweight” recommendation on October 24, 2023. Citigroup started covering the stock on October 12, 2023. It rated KRYS as “a Buy”.
Price Performance Review of KRYS
On Friday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock jump 2.47% to $148.39. Over the last five days, the stock has lost -2.96%. Krystal Biotech Inc shares have fallen nearly -5.28% since the year began. Nevertheless, the stocks have risen 17.78% over the past one year. While a 52-week high of $219.34 was reached on 01/07/25, a 52-week low of $107.50 was recorded on 01/14/25. SMA at 50 days reached $172.45, while 200 days put it at $177.95.
Levels Of Support And Resistance For KRYS Stock
The 24-hour chart illustrates a support level at 146.46, which if violated will result in even more drops to 144.52. On the upside, there is a resistance level at 149.74. A further resistance level may holdings at 151.08. The Relative Strength Index (RSI) on the 14-day chart is 37.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -6.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.00%. Stochastics %K at 23.82% indicates the stock is a holding.
How much short interest is there in Krystal Biotech Inc?
A steep rise in short interest was recorded in Krystal Biotech Inc stocks on 2024-12-31, dropping by -0.28 million shares to a total of 3.37 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 3.65 million shares. There was a decline of -8.32%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 07, 2023 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $154 price target.
